BRMU8602979U - medicine "atorvastatin + metformin" in combination form for cardiovascular disease - Google Patents
medicine "atorvastatin + metformin" in combination form for cardiovascular diseaseInfo
- Publication number
- BRMU8602979U BRMU8602979U BRMU8602979U BRMU8602979U BR MU8602979 U BRMU8602979 U BR MU8602979U BR MU8602979 U BRMU8602979 U BR MU8602979U BR MU8602979 U BRMU8602979 U BR MU8602979U
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- atorvastatin
- medicine
- cardiovascular disease
- metformine
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
O "MEDICAMENTO "ATORVASTATINA + METFORMINA EM FORMA COMBINADA PARA DOENçAS CARDIO VASCULARES," resuma-se a combinação de dois medicamentos utilizados contra as doenças cardiovasculares são a principal causa de morte em nosso país. Há nítida correlação entre o ganho ponderal e o excesso de peso com risco de doenças cardiovasculares. O excesso de peso predispóe a estas doenças devido anormalidades no metabolismo dos lípides, glicose e pressão arterial. A resistência à insulina 1 hiperinsulinemia parece ser um fator de risco independente de outros fatores de risco associados, como a obesidade, hiperlipidemia e hipertensão, tanto em homens como em mulheres. A insulina e os fatores de crescimento semelhantes à insulina estimulam a atividade das células musculares lisas e estão envolvidas na aterogênese e mesmo na reestenose que se segue ao reparo coronário pela angioplastia. Outros efeitos da insulina estão relacionados aos mecanismos que contribuem para o desenvolvimento tanto da hipertensão como da dislipidemia. O MEDICAMENTO "ATORVASTATINA + METFORMINA" EM FORMA COMBINADA PARA DOENCAS CARDIO VASCULARES, diminuindo a resistência insulínica, a pressão arterial, o ganho ponderal e melhorando o perfil lipídico destes paciente, reduziriam muito a probabilidade de eventos cardiovasculares e consequentemente o óbito dessa natureza em nossa população."ATORVASTATIN + METFORMINE" MEDICINE "COMBINED FOR CARDIO VASCULAR DISEASES," summarizes the combination of two drugs used against cardiovascular disease are the leading cause of death in our country. There is a clear correlation between weight gain and excess weight at risk for cardiovascular disease Overweight predisposes to these diseases due to abnormalities in lipid metabolism, glucose and blood pressure Insulin resistance 1 hyperinsulinemia appears to be a risk factor independent of other associated risk factors such as obesity , hyperlipidemia and hypertension in both men and women Insulin and insulin-like growth factors stimulate smooth muscle cell activity and are involved in atherogenesis and even restenosis following coronary repair by angioplasty. insulin are related to the mechanisms that contribute to the development of hypertension and dyslipidemia. "ATORVASTATIN + METFORMINE" MEDICINE COMBINED FOR CARDIO VASCULAR DISEASES, decreasing insulin resistance, blood pressure, weight gain and improving the lipid profile of these patients would greatly reduce the likelihood of cardiovascular events and consequently the death of this nature in our population.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRMU8602979 BRMU8602979U (en) | 2006-11-16 | 2006-11-16 | medicine "atorvastatin + metformin" in combination form for cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRMU8602979 BRMU8602979U (en) | 2006-11-16 | 2006-11-16 | medicine "atorvastatin + metformin" in combination form for cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRMU8602979U true BRMU8602979U (en) | 2008-09-30 |
Family
ID=39776191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRMU8602979 BRMU8602979U (en) | 2006-11-16 | 2006-11-16 | medicine "atorvastatin + metformin" in combination form for cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRMU8602979U (en) |
-
2006
- 2006-11-16 BR BRMU8602979 patent/BRMU8602979U/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRMU8602999U (en) | medicine "rosuvastatin + metformin" in combination form for cardiovascular disease | |
| Vermeulen et al. | Bioavailability and kinetics of sulforaphane in humans after consumption of cooked versus raw broccoli | |
| Young et al. | Milrinone: a preliminary review of its pharmacological properties and therapeutic use | |
| Huang et al. | Repurposing psychiatric drugs as anti-cancer agents | |
| Belcaro et al. | Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients | |
| Jouad et al. | Hypoglycaemic effect of Rubus fructicosis L. and Globularia alypum L. in normal and streptozotocin-induced diabetic rats | |
| Nisly et al. | Canagliflozin, a new sodium–glucose cotransporter 2 inhibitor, in the treatment of diabetes | |
| da Luz et al. | Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats | |
| Arnaoutis et al. | The effect of hypohydration on endothelial function in young healthy adults | |
| Koyasu et al. | Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease | |
| Hennekens et al. | Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions | |
| Skilton et al. | Endothelial dysfunction and arterial abnormalities in childhood obesity | |
| Kokkinaki et al. | Chemically synthesized Secoisolariciresinol diglucoside (LGM2605) improves mitochondrial function in cardiac myocytes and alleviates septic cardiomyopathy | |
| Lien et al. | Short-term exercise training attenuates acute doxorubicin cardiotoxicity | |
| CN102958362A (en) | Resveratrol-containing compositions and methods of use | |
| ECSP055914A (en) | PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR THERAPY OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES | |
| Rokyta et al. | Post-pyloric enteral nutrition in septic patients: effects on hepato-splanchnic hemodynamics and energy status | |
| Almansour et al. | In vivo investigation on the chronic hepatotoxicity induced by sertraline | |
| BRMU8602970U (en) | medicine "telmisartam + metformin" in combination form for cardiovascular disease | |
| US20160346340A1 (en) | Compositions including milk thistle and methods for the treatment of various disorders using the same | |
| BRMU8602979U (en) | medicine "atorvastatin + metformin" in combination form for cardiovascular disease | |
| BRMU8602991U (en) | medicine "candesartan + metformin" in combination form for cardiovascular disease | |
| BRPI0516811A (en) | compounds, cosmetic composition, cosmetic use of a composition, use of a compound and pharmaceutical composition | |
| BRMU8602968U (en) | medicine "ramipril + metformin" in combination form for cardiovascular disease | |
| BRMU8403417U (en) | simvastatin + metformin combined medicine for cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of an application: publication of a patent application or of a certificate of addition of invention | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012. |